Sept 21 (Reuters) – Johnson & Johnson said on Monday its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study, bringing the drug a step closer to expanding beyond its
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Sept 21 (Reuters) - Canada's main stock index opened higher on Monday, led by gains…
By Manya Saini Sept 21 (Reuters) - Oura is targeting a fully diluted valuation of…
By David Lawder and Susan Heavey WASHINGTON, Sept 21 (Reuters) - Senior US and Chinese…
JOHANNESBURG, Sept 21 (Reuters) - South African police have arrested three people over the death…
L-R: Mr. Chinmay Sawant, Business Development Manager, Simandhar Education; Dr. Tessy Thadathil, Vice Principal, Symbiosis…
Sept 21 (Reuters) - Recursion Pharmaceuticals, Inc. : * TEMPUS AND RECURSION EXTEND EXISTING DATA…